Prognostic and predictive markers in canine tumours: rationale and relevance. A review.
Cancer is one of the most common causes of death in dogs. The availability of multiple treatment modalities and novel therapeutic targets make the correct diagnosis, prognostic stratification, and the identification of treatment effect predictive factors an issue of major debate in cancer management. Selection of high and low risk patients and the type of systemic or local treatment is important in cancer management. The search for better prognostic markers and predictive factors is now focused on the molecular mechanisms which underlie tumour behaviour, such as altered cell cycle progression, proliferation, apoptosis, and angiogenesis. The ultimate goal is to identify reliable markers that can accurately diagnose and stage a tumour and predict tumour's clinical behaviour, prognosis and response to therapy. In this review, the current state of prognostication in canine tumours and promising new molecular markers are discussed. The markers are allocated to four groups according to their function: (i) proliferation markers, (ii) apoptosis, (iii) extracellular matrix and cell adhesion molecules, (iv) angiogenesis and (v) cell cycle regulators. Clinicopathological factors and histopathological grading remain the most practical parameters in decision-making. Although experimental research has shown that molecular markers have a good potential to be used as diagnostic, prognostic or predictive markers in canine tumours, insufficient evidence exists on their efficacy for routine use in veterinary oncology.
Mukaratirwa
S
S
Department of Paraclinical Studies, Pathology Section, Faculty of Veterinary Science, University of Zimbabwe, Mount Pleasant, Harare. tmukaratirwa@vet.uz.ac.zw
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D014408:Biomarkers, Tumor; D004283:Dog Diseases / Q000175:diagnosis* / Q000188:drug therapy; D004285:Dogs; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*; D009389:Neovascularization, Pathologic; D011379:Prognosis
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor